Related Experiment Videos
Iontophoresis: from the lab to the bed side
M Halhal1, G Renard, Y Courtois
1INSERM U 450, 15 rue de l'Ecole de Médecine, 75006 Paris, France.
Experimental Eye Research
|April 27, 2004
Summary
Ocular iontophoresis effectively treats corneal graft rejection. This method, using methylprednisolone sodium succinate (MP), reversed rejection in 88% of patients, improving visual acuity with minimal side effects.
Area of Science:
- Ophthalmology
- Drug Delivery Systems
- Corneal Transplantation
Background:
- Pioneering work in the 1970s-80s established iontophoresis as a potential ocular therapy.
- Advances in understanding eye tissue interactions and device design enable clinical application.
- Corneal graft rejection remains a significant challenge in ophthalmology.
Purpose of the Study:
- To evaluate the efficacy of an iontophoresis device for treating active corneal graft rejection.
- To assess the impact of iontophoresis treatment on visual acuity and patient outcomes.
- To determine the safety and side-effect profile of ocular iontophoresis.
Main Methods:
- Seventeen patients with active corneal graft rejection received iontophoresis treatment.
- Methylprednisolone sodium succinate (MP) was delivered via an ocular iontophoresis device (Eyegate).
- A 1.5 mA electrical current was applied for 4 minutes daily over 3 consecutive days.
Main Results:
- Complete reversal of rejection was observed in 15 out of 17 treated eyes (88%).
- Mean best corrected visual acuity improved significantly from 0.06 to 0.37 post-treatment.
- No significant side-effects were reported during the mean follow-up of 13.7 months.
Conclusions:
- Ocular iontophoresis of MP is a promising alternative for managing active corneal graft rejection.
- This treatment offers an effective alternative to frequent eye drops or intravenous corticosteroids.
- Iontophoresis provides a safe and efficient method for delivering medication to the eye.